title: Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guérin therapy.
abstract: OBJECTIVE
  To evaluate the correlation between the overexpression of mutant protein p53 and disease recurrence and progression in patients treated with bacillus Calmette-Guérin (BCG) intravesical therapy for T1G3 bladder cancer.
  
  
  METHODS
  We analyzed the outcome of 29 consecutive patients treated for T1G3 bladder tumor with transurethral resection. Patients previously treated for a bladder tumor, those who underwent incomplete resection, and those in whom no assessment of the muscle cell layer was possible were excluded from the study. p53 overexpression was determined using monoclonal p53-DO7 antibody, with a 20% cutoff for definition of positivity. After the initial transurethral resection, all patients were treated with Pasteur BCG (75 mg in 50 mL saline), weekly for 6 weeks. The correlation between p53 overexpression and disease recurrence and progression was assessed by the Fisher exact test.
  
  
  RESULTS
  The median follow-up was 36.7 months (range 1 to 108). Of the 29 patients, 18 (62.1%) were p53 positive and 11 (37.9%) were p53 negative. Both groups were similar according to age, tumoral substage (T1a/T1b), association with carcinoma in situ, multifocality, and length of follow-up. The recurrence rate was 54.4% in the p53-negative group versus 38.9% in the p53-positive group (P = 0.47). The progression rate was 18.2% in the p53-negative group versus 33.3% in the p53-positive group (P = 0.67).
  
  
  CONCLUSIONS
  These findings suggest that overexpression of p53, as determined immunohistochemically, has no predictive value for recurrence and progression in T1G3 bladder cancers treated with intravesical BCG.
authors.affiliation: Department of Urology, Bichat-Claude Bernard Hospital, Paris, France.
authors.forename: Michael
authors.initials: M
authors.lastname: Peyromaure
authors.forename: Sun
authors.initials: S
authors.lastname: Weibing
authors.forename: Philippe
authors.initials: P
authors.lastname: Sebe
authors.forename: Patrice
authors.initials: P
authors.lastname: Verpillat
authors.forename: Marianne
authors.initials: M
authors.lastname: Toublanc
authors.forename: Marie Christine
authors.initials: MC
authors.lastname: Dauge
authors.forename: Laurent
authors.initials: L
authors.lastname: Boccon-Gibod
authors.forename: Vincent
authors.initials: V
authors.lastname: Ravery
mesh_terms: D000283:Administration, Intravesical; D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002278:Carcinoma in Situ / Q000175:diagnosis / Q000188:drug therapy; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis / Q000188:drug therapy; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*
chemical_list: D001500:BCG Vaccine; D014408:Biomarkers, Tumor; D016159:Tumor Suppressor Protein p53